Article: Neurocrine Biosciences Reports Positive Results From First Phase III Clinical Trial With indiplon-IR in 593 Subjects With Transient Insomnia.

Indiplon-IR Demonstrates Statistically Significant Improvement in Multiple Sleep Endpoints

Neurocrine Biosciences, Inc. today announced positive results from the Company's first Phase III clinical trial with indiplon-IR capsules, achieving both primary and secondary endpoints of sleep initiation. The study enrolled 593 subjects with Transient Insomnia. Results demonstrated that indiplon-IR was safe, well tolerated, and effective in these subjects with Transient Insomnia, achieving rapid sleep induction without next day residual effects. The study was a randomized, double-blind, placebo-controlled, parallel group Phase III clinical trial designed to assess the ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!